Square Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Square Pharmaceuticals has a total shareholder equity of BDT121.8B and total debt of BDT1.5B, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are BDT128.2B and BDT6.4B respectively. Square Pharmaceuticals's EBIT is BDT17.7B making its interest coverage ratio -4.3. It has cash and short-term investments of BDT48.4B.
Belangrijke informatie
1.3%
Verhouding schuld/eigen vermogen
৳1.55b
Schuld
| Rente dekkingsratio | -4.3x |
| Contant | ৳48.40b |
| Aandelen | ৳121.79b |
| Totaal verplichtingen | ৳6.40b |
| Totaal activa | ৳128.19b |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: SQURPHARMA's short term assets (BDT68.1B) exceed its short term liabilities (BDT4.7B).
Langlopende schulden: SQURPHARMA's short term assets (BDT68.1B) exceed its long term liabilities (BDT1.7B).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: SQURPHARMA has more cash than its total debt.
Schuld verminderen: SQURPHARMA's debt to equity ratio has increased from 0% to 1.3% over the past 5 years.
Schuldendekking: SQURPHARMA's debt is well covered by operating cash flow (916.8%).
Rentedekking: SQURPHARMA earns more interest than it pays, so coverage of interest payments is not a concern.